Baseline expression of immune gene modules in blood is associated with primary response to anti-TNF therapy in Crohn’s disease patients

Benjamin Y H Bai,Mark Reppell,Nizar Smaoui,Jeffrey F Waring,Valerie Pivorunas,Heath Guay,Simeng Lin,Neil Chanchlani,Claire Bewshea,James R Goodhand,Inflammatory Bowel Disease Pharmacogenetics Study Group,Nicholas A Kennedy,Tariq Ahmad,Carl A Anderson,
DOI: https://doi.org/10.1093/ecco-jcc/jjad166
2023-09-30
Journal of Crohn's and Colitis
Abstract:Abstract Background and Aims Anti-TNF therapy is widely used for treatment of inflammatory bowel disease, yet many patients are primary non-responders, failing to respond to induction therapy. We aimed to identify blood gene expression differences between primary responders and primary non-responders to anti-TNF monoclonal antibodies (infliximab and adalimumab); and to predict response status from blood gene expression and clinical data. Methods The Personalised Anti-TNF Therapy in Crohn’s Disease (PANTS) study is a UK-wide prospective observational cohort study of anti-TNF therapy outcome in anti-TNF naive Crohn’s disease patients (ClinicalTrials.gov identifier: NCT03088449). Blood gene expression in 324 unique patients was measured by RNA-seq at baseline (week 0), and at weeks 14, 30, and 54 after treatment initiation (total sample size = 814). Results After adjusting for clinical covariates and estimated blood cell composition, baseline expression of major histocompatibility complex, antigen presentation, myeloid cell enriched receptor, and other innate immune gene modules was significantly higher in anti-TNF responders versus non-responders. Expression changes from baseline to week 14 were generally of consistent direction but greater magnitude (i.e. amplified) in responders, however interferon-related genes were upregulated uniquely in non-responders. Expression differences between responders and non-responders observed at week 14 were maintained at week 30 and week 54. Prediction of response status from baseline clinical data, cell composition, and module expression was poor. Conclusions Baseline gene module expression was associated with primary response to anti-TNF therapy in PANTS patients. However, these baseline expression differences did not predict response with sufficient sensitivity for clinical use.
gastroenterology & hepatology
What problem does this paper attempt to address?